ALEXIS KILBOURN: Open Payments
NPI 1952945750 · MANCELONA, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$783 in 39 payments from 13 companies in 2025. Trend: 2023 $589 · 2024 $361 · 2025 $783
Food & beverage: $693Education: $90
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $199 |
| Novo Nordisk Inc | 6 | $148 |
| Astellas Pharma US Inc | 3 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $121 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Amgen Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Exact Sciences Corporation | 1 | $15 |
Products named: CAPLYTA, UBRELVY, VRAYLAR, Wegovy, Auvelity, Veozah, QULIPTA, Ozempic.
Industry payments across MI — which companies pay providers there.
